September 2012 • Issue 37

Blood and Transplant

Blood and Transplant Information for hospitals served Matters Matters

Incide

marac			
The Transfusion Safety Team of the Biomedical Excellence for Safer Transfusion (BEST) Collaborative		Who Uses Cryoprecipitate and Why?	
		A Survey Usage in Three English Regions	20
	4	Granulocytes in Additive Solution and	
Stored RBCS In Critically III Patients	6	Plasma (GASP): New for England and	
Supporting Safer Transfusions	7	North Wales in October 2012	22
Haemolytic Disease of the Fetus and Newborn and Use of Anti-D Immunoglobulin – An Update		The UK Donation Ethics Committee	25
		Haematopoietic Stem Cell Mobilisation	
	9	- Current Concepts	27
Clinical Use of Blood: Update on the Aim II Trial	12	The Role of Donor Optimisation in	y Usage in Three English Regions cytes in Additive Solution and GASP): New for England and Yales in October 2012 Donation Ethics Committee opoietic Stem Cell Mobilisation at Concepts of Donor Optimisation in ntation on Our 'Practice of Transfusion' tic Reviews estions 23 24 25 27 27 28 29 29 20 20 21 22 23 24 25 26 27 27 28 29 29 20 20 21 22 23 24 25 26 27 27 28 29 20 20 21 22 23 24 25 26 27 27 28 29 29 20 20 21 22 23 24 25 26 27 27 28 29 29 20 20 21 22 23 24 25 26 27 27 28 29 29 20 20 20 21 22 23 24 25 26 27 27 28 29 29 20 20 20 20 20 20 20 20
Meeting the Increasing Requirements for		Transplantation	29
Platelet Supply to Hospitals – A Success Story	4.4	Update on Our 'Practice of Transfusion'	
of Co-operation along the Supply Chain	14	Systematic Reviews	31
Patient Empowerment and Involvement in Blood Transfusion	16	CPD Questions	33
III BIOOG ITAIISTUSIOIT	10	Clinical Case Studies	35
The Blood Stocks Management Scheme			
- Into the Future	18	Diary Dates	39



The Transfusion Safety Team of the Biomedical Excellence for Safer Transfusion (BEST) Collaborative

BEST is an international research organisation that works collaboratively to explore ways to improve transfusion-related services through standardisation of laboratory methods, the development of new procedures, and clinical trials. BEST was established in 1991 as a collaboration between scientists and manufacturers active in transfusion medicine research. It has recently encompassed blood services as members.

The activities of BEST are co-ordinated through its team structure and twice yearly two-day meetings. Until 2011, there were four Teams, namely Conventional Components, Clinical Studies, Cellular Therapy and Transfusion Safety. A Team for Donor Studies has recently been established to undertake studies in this under-researched field of transfusion medicine.

The BEST Transfusion Safety Team conducts collaborative international studies that address questions regarding the safe transfusion of blood and components. Its projects are based principally in hospitals related to BEST members, and include pilot exploratory studies, definitive large-scale studies, randomised trials, surveys, laboratory-based investigation and qualitative research. While principally focused on countries with advanced healthcare, projects suited to countries with emerging economies are also conducted. The founding team leaders of the Transfusion Safety Team were Sunny Dzik (Boston) and Cees Smit Sibinga (Groningen). The current team leaders are Mark Fung (Vermont) and Mike Murphy (Oxford).

Recent Completed Projects of the Transfusion Safety Team include:

A study of the frequency of mis-labelled and miscollected blood samples used for pre-transfusion testing. This study assessed the frequency of mis-labelled and mis-collected samples taken for blood grouping and antibody screening. Mis-labelled samples were defined as those not meeting local criteria for acceptance by the laboratory. Mis-collected samples (Wrong-Blood-in-Tube or WBIT) were defined as samples whose blood group result differed from the result on file from prior testing. WBIT rates were corrected for the proportion of repeat samples and for undetectable errors due to chance collection of blood from the wrong patient with the same ABO group. 62 hospitals in ten countries provided data on the frequency of mis-labelled and mis-collected samples during a period of at least three months. Based on the results from over 690,000 samples, the median rate for mis-labeling was one in every 165 samples (6.1 per 1,000). Mis-collected samples demonstrating WBIT

occurred at a median rate of one in every 1,986 samples (0.5 per 1,000). There was great variation worldwide in the reported frequency of mis-labelled samples probably resulting from variation in policies for sample acceptance. Mis-collected samples occurred at a more constant rate. It was recommended that rates of mis-labelled samples and WBIT could be tracked as key indicators of performance of an important step in the clinical transfusion process.

A randomised cluster-design study on the utility of a low-cost method to reduce the risk of mistransfusion clerical errors at the bedside. A trial was conducted to assess the effectiveness of a simple intervention designed to improve performance of the bedside check and the durability of any effect. The intervention was a tag on blood bags reminding staff to check the patient's wristband. The tag was positioned in such a way that the transfusionist was required to remove the tag in order to spike the unit. The intervention was tested in a multicentre cluster-randomised controlled trial at 12 participating hospitals in six countries. The primary endpoint was the proportion of patients transfused with red cell units for whom the key elements of the bedside check were all correctly completed. Combining data from all participating hospitals, the bedside check was correctly performed in only 37% of transfusions during the baseline audit period. There was no evidence of a favourable effect of the intervention immediately after its introduction. The robust study design developed for this study could be applied to investigate other interventions to improve the safety of bedside transfusion practice.

A practical tool for the use of statistical process control to monitor transfusion process. Statistical Process Control (SPC) is a recognised methodology to monitor the performance of a critical process. An easy-to-use SPC method was developed and applied for monitoring the process of sample labelling and collection in ten hospitals in five countries. The method proved suitable for monitoring sample collection. Based on the experience of the hospitals in this study, recommendations were provided about how best to use the tool. SPC could be applied to other critical steps in the transfusion processes as a tool for biovigilance, and to develop regional or national performance standards for pre-transfusion sample collection. The software tool is freely available to all from the BEST website: http://www.bestcollaborative.org/.

A qualitative study using focus group feedback to explore weaknesses in the bedside clerical check prior to transfusion. Focus group discussions and interviews were conducted at six hospitals in five countries. The findings included that staff were aware of the seriousness of errors and were receptive to continuous monitoring; the focus was on checking the bag label with the paperwork rather than the bag label with the patient at the bedside; training methods varied with most perceived to have minimal effectiveness; access to policies was challenging and keeping up-to-date was difficult. Other factors contributing to errors included workload distractions and interruptions, and familiarity or lack of familiarity with patients. It was concluded that multiple factors contribute to errors during the pre-transfusion checking limiting the effectiveness of any individual intervention designed to improve safety. Areas of further research to improve safety of blood administration were identified.

Current Projects Include:

- A study to model the effect of changes in red cell storage on the inventory of blood available for patient use in hospitals.
- Development of a tool to assess the knowledge of transfusion medicine in junior doctors.
- A trial to investigate the role of patient involvement to improve patient safety.
- A trial to evaluate whether feedback of current utilisation to individual physicians will lead to improved blood product utilisation.

Further information about the BEST Collaborative is available on its website: http://www.bestcollaborative.org.

Walter 'Sunny' Dzik
MD Co-Director, Blood Transfusion Service
Massachusetts General Hospital
Associate Professor, Harvard Medical School
Boston, MA, USA

References:

Dzik W H, Murphy M F, Andreu G, Heddle N, Hogman C, Kekomaki R, *et al* (2003). An International Study of the Performance of Blood Sample Collection. *Vox Sanguinis*, **85**: 40-47.

Dzik W, Beckman N, Selleng K, Heddle N, Szczepiorkowski Z, Wendel S *et al* (2008). Errors in Patient Specimen Collection: Application of Statistical Process Control. *Transfusion*, **48**: 2143-2151.

Heddle N M, Fung M, Hervig T, Szczepiorkowski Z, Toretta L, Arnold E *et al* for the BEST Collaborative. (In Press). Can we Prevent Transfusion of the Wrong Blood? A Qualitative Evaluation for Safer Transfusion (QUEST). *Transfusion*.

Murphy M F, Casbard A C, Ballard S, Shulman I A, Heddle N, Aubuchon J P *et al* on behalf of the BEST Research Collaborative (2007). Prevention of Bedside Errors in Transfusion Medicine (PROBE-TM) Study: A Cluster-Randomised, Matched-Paired-Clinical Areas Trial of a Simple Intervention to Reduce Errors in the Pre-Transfusion Bedside Check. *Transfusion*, **47**: 771-780

Correspondence:

Professor Mike Murphy Clinical Director, Patients NHSBT, John Radcliffe Hospital Oxford, UK

Email: mike.murphy@nhsbt.nhs.uk

Associate Professor Mark K Fung, MD PhD
Department of Pathology
University of Vermont College of Medicine
Medical Director, Blood Bank
Medical Director, Tissue Typing Laboratory
Fletcher Allen Health Care
Burlington, VT 05401, USA

Professor Dr. Cees Th. Smit Sibinga, MD, PhD, FRCP Edin and FRCPath
Professor of International Development of Transfusion Medicine (IDTM) at the University of Groningen, The Netherlands
Director of ID Consulting for International Development of Transfusion Medicine (IDTM)